ID | 31972 |
JaLCDOI | |
FullText URL | |
Author |
Ishida, Makoto
Murakami, Kazuharu
Sakurai, Masaru
|
Abstract | It is well known that antecedent term delivery and metastasis to sites other than the lungs and vagina are high risk factors for patients with gestational trophoblastic neoplasia. Here we report on a patient with choriocarcinoma who presented with brain and lung metastases after term delivery and was treated by EMA-CO chemotherapy. A 31-year-old woman delivered a healthy infant at term. Frequent episodes of hemoptysis occurred beginning 3 weeks after the delivery. On admission to our hospital, she had lesions in the uterus, lungs and brain as well as motor aphasia and hemiplagia. The pretreatment beta-hCG level was 21,000 ng/ml and the WHO score was 16 (high-risk group). The EMA-CO regimen was administrated as first-line chemotherapy and the patient achieved complete remission after 7 courses. Treatment was terminated after 11 courses and maintained with etoposide (25 mg/day) for 6 months. The patient has remained in complete remission for more than 16 years without other adjuvant therapies. We believe that EMA-CO can currently be considered the regimen of first choice for most high-risk patients with gestational trophoblastic neoplasia in view of its effectiveness and excellent tolerability. |
Keywords | choriocarcinoma
term delivery
EMA-CO chemotherapy
metastasis
|
Amo Type | Article
|
Publication Title |
Acta Medica Okayama
|
Published Date | 2005-10
|
Volume | volume59
|
Issue | issue5
|
Publisher | Okayama University Medical School
|
Start Page | 253
|
End Page | 258
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT |